Published in J Am Heart Assoc on December 23, 2015
Within-the-Clinic Shared Decision for an Over-the-Counter Medication. J Am Heart Assoc (2015) 0.75
Adherence to medication. N Engl J Med (2005) 39.77
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med (1989) 13.83
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64
Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2009) 7.34
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA (2008) 6.15
Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA (2006) 5.95
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol (2003) 3.26
The "Million Hearts" initiative--preventing heart attacks and strokes. N Engl J Med (2011) 2.93
Implementation of the third universal definition of myocardial infarction after coronary artery bypass grafting: a survey study in Western Europe. J Am Heart Assoc (2015) 2.78
Deaths preventable in the U.S. by improvements in use of clinical preventive services. Am J Prev Med (2010) 2.73
Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med (2011) 2.65
Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation (2008) 2.42
Trends in blood pressure, hypertension control, and stroke mortality: the Minnesota Heart Survey. Am J Med (2006) 2.10
Population risk of cardiovascular disease: the Minnesota Heart Survey. J Chronic Dis (1985) 1.65
Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med (2006) 1.48
The discovery of aspirin's antithrombotic effects. Tex Heart Inst J (2007) 1.45
Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med (2007) 1.43
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Circulation (2015) 1.33
Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J (1996) 1.20
Cardiovascular disease risk reduction in the Behavioral Risk Factor Surveillance System. Am J Prev Med (2004) 1.09
Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials. PLoS One (2013) 1.03
Cardiovascular risk factor change--1973-74 to 1980-82: the Minnesota Heart Survey. J Clin Epidemiol (1988) 1.01
Acetylsalicylic acid, possible preventive of coronary thrombosis. Ann West Med Surg (1950) 0.97
Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. Circulation (2015) 0.94
Aspirin use among adults in the U.S.: results of a national survey. Am J Prev Med (2015) 0.94
Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarction. Am Heart J (2012) 0.91
Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry. Circ Cardiovasc Qual Outcomes (2010) 0.90
The aspirin controversy in primary prevention. Curr Opin Cardiol (2012) 0.88
Confirmation of reported aspirin use in community studies: utility of serum thromboxane B2 measurement. Clin Appl Thromb Hemost (2013) 0.86
Use of low-dose aspirin as secondary prevention of atherosclerotic cardiovascular disease in US adults (from the National Health Interview Survey, 2012). Am J Cardiol (2015) 0.84
Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. Circulation (2015) 0.81
A comparison of every-third-day versus daily low-dose aspirin therapy on serum thromboxane concentrations in healthy men and women. Clin Appl Thromb Hemost (2001) 0.77